(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
09 April 2020 (09.04.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/070539 A1

(51) International Patent Classification:
A61K 31/4418 (2006.01) *A61P 19/06* (2006.01)
A61K 31/70 (2006.01) *A61P 9/04* (2006.01)
A61K 31/426 (2006.01) *A61P 13/12* (2006.01)
A61K 31/519 (2006.01)

(21) International Application Number:
PCT/IB2018/057612

(22) International Filing Date:
01 October 2018 (01.10.2018)

(25) Filing Language: English

(26) Publication Language: English

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; SE-151-85 Södertälje (SE).

(72) Inventors: **HOEGSTEDT, Johan**; Astrazeneca Pharmaceuticals LP, 1800 Concord Pike, Wilmington, Delaware 19850-5437 (US). **MACKAY, James**; Astrazeneca Pharmaceuticals LP, 1800 Concord Pike, Wilmington, Delaware 19850-5437 (US). **JOHNSSON, Eva**; Astrazeneca AB, SE-151-85 Södertälje (SE).

(74) Agent: **LEESE, Mathew**; AstraZeneca UK Limited, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge, Cambridgeshire CB2 0AA (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:
— *with international search report (Art. 21(3))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(54) Title: COMPOSITIONS FOR REDUCING SERUM URIC ACID

(57) Abstract: The present disclosure provides compositions comprising verinurad, a xanthine oxidase inhibitor, and dapagliflozin useful in the reduction of serum uric acid levels, formulations containing them, and methods using them. In some embodiments, the methods and compositions described herein are used in the treatment or prevention of conditions associated with hyperuricemia, such as chronic kidney disease, heart failure, and gout.

WO 2020/070539 A1